1 National Vital Statistics System, Centers for Disease Control and Prevention. “GMWKI: Total deaths for each cause by 5-year age groups, United States, 1999-2006+,” last modified November 12, 2009, www.cdc.gov/nchs/nvss/mortality/gmwki.htm; J. Xu et al., “Deaths: Final Data for 2007,” National Vital Statistics Reports 58, no. 19 (2010); K.D. Kochanek et al., “Deaths: Preliminary Data for 2009,” National Vital Statistics Reports 59, no. 4 (2011).
2 K.D. Kochanek et al., “Deaths: Preliminary Data for 2009.”
3 S.M. McGlone et al., “The Economic Burden of Clostridium difficile,” Clin Microbiol Infect (2011).
4 R. Ricciardi et al., “Increasing Prevalence and Severity of Clostridium difficile Colitis in Hospitalized Patients in the United States,” Arch Surg 142, no. 7 (2007): 624-31; discussion 31.
5 F. Barbut and J.C. Petit, “Epidemiology of Clostridium difficile-Associated Infections,” Clin Microbiol Infect 7, no. 8 (2001): 405-10.
6 V.K. Viswanathan, M.J. Mallozzi, and G. Vedantam, “Clostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventions,” Gut Microbes 1, no. 4 (2010): 234-42.
7 H. Pituch, “Clostridium difficile is no longer just a nosocomial infection or an infection of adults,” Int J Antimicrob Agents 33 Suppl 1 (2009): S42-5.
8 “Severe Clostridium difficile-Associated Disease in Populations Previously at Low Risk—Four States, 2005,” MMWR Morb Mortal Wkly Rep 54, no. 47 (2005): 1201-5.
9 P.K. Kutty et al., “Risk Factors for and Estimated Incidence of Community-Associated Clostridium difficile Infection, North Carolina, USA,” Emerg Infect Dis 16, no. 2 (2010): 197-204.
10 A.N. Ananthakrishnan, “Clostridium difficile infection: epidemiology, risk factors and management,” Nat Rev Gastroenterol Hepatol 8, no. 1 (2011): 17-26.
11 T. Pelaez et al., “Reassessment of Clostridium difficile Susceptibility to Metronidazole and Vancomycin,” Antimicrob Agents Chemother 46, no. 6 (2002): 1647-50.
12 A. Dworczynski, B. Sokol, and F. Meisel-Mikolajczyk, “Antibiotic resistance of Clostridium difficile isolates,” Cytobios 65, no. 262-263 (1991): 149-53.
13 U.S. Food and Drug Administration, “FDA approves treatment for Clostridium difficile infection,” news release, May 27, 2011, www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm257024.htm.
14 A. Pollack, “F.D.A. Approves Drug to Treat Hospital Scourge,” New York Times, May 27, 2011, www.nytimes.com/2011/05/28/health/28drug.html.
15 R.M. Dallal et al, “Fulminant Clostridium difficile: An Underappreciated and Increasing Cause of Death and Complications,” Ann Surg 235, no. 3 (2002): 363-72.
16 Based on data from, M.P. Heron et al., “Deaths: Final Data for 2006,” National Vital Statistics Reports 57, no. 14 (2009).